Producer
Indena S.p.A.
Italian botanical extract specialist headquartered in Milan; founded 1921 as a subsidiary of Recordati pharmaceutical group. Indena is the world's leading non-Chinese manufacturer of plant-derived pharmaceutical APIs including camptothecin-class compounds, paclitaxel, and other oncology botanicals. Indena sources Camptotheca acuminata plant material from China (and limited cultivation trials in Europe) and processes it at its Italian facilities under EMA GMP certification, supplying camptothecin and camptothecin derivatives to European and U.S. pharmaceutical manufacturers. Indena's non-China GMP-certified supply is particularly valuable to Western pharmaceutical companies seeking to diversify supply away from Chinese botanical sources for critical oncology APIs.
2
Inputs supplied
1
Goods downstream
2
Facilities
0
Stories
What they make
2 inputs Indena S.p.A. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Indena S.p.A. makes — pick one to see the full supply chain.
Where they make it
2 facilities
Indena S.p.A. Milan & Settala Production Sites →
ITLombardy · manufacturing
Indena's primary extraction and purification facilities in Milan and Settala (Lombardy). EMA GMP-certified; processes plant material imported from China and other botanical sources into camptothecin, paclitaxel, silymarin, and other phytochemical APIs. Indena's Italian GMP certification is a critical differentiator — it is the primary non-Chinese GMP-certified source for camptothecin-class compounds qualified for Western pharmaceutical manufacturing. Capacity is a fraction of Chinese producers but serves as the Western world's botanical extraction bridge. Source: https://www.indena.com/manufacturing-quality/manufacturing/
Indena S.p.A. Milan Botanical API Facility →
ITLombardy · manufacturing
Indena's Milan and Settala (Lombardy) facilities produce 10-deacetylbaccatin III (10-DAB) and paclitaxel API via semi-synthesis from European yew (Taxus baccata) needle clippings sourced from European yew plantations. Also produces docetaxel, vincristine, vinblastine, and artemisinin from botanical sources. Indena's Milan operation is the largest European botanical pharmaceutical extract manufacturing site. Source: https://www.indena.com/our-facilities/
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Oncology APIs (Botanical)
45%Pharmaceutical Botanical Extracts
30%Nutraceuticals & Cosmetics Ingredients
25%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Concentration2023
Indena S.p.A. (Milan; private; founded 1921) is the world's oldest and largest producer of plant-derived pharmaceutical APIs at commercial scale in the Western world — and almost no one in the pharmaceutical industry knows the company exists. Indena manufactures the APIs for: paclitaxel and docetaxel (taxanes for cancer, from Taxus baccata needles); vincristine and vinblastine (vinca alkaloids for cancer, from Catharanthus roseus); artesunate and artemether (antimalarials, from Artemisia annua); silymarin (liver protection, from Milk Thistle); Ginkgo biloba extract (cognitive pharmaceutical, from Ginkgo leaves); colchicine (gout treatment, from Crocus autumnalis). Indena is a private Italian company with no publicly traded comparable. Its portfolio collectively represents life-saving cancer chemotherapy (taxanes, vincas), malaria treatment (artemisinins), and the world's most widely used herbal cognitive supplement (Ginkgo) — all from the same Lombard botanical extraction company. BMS chose Indena as its semi-synthesis partner to rescue Taxol from the Pacific yew extinction crisis; WHO chose Indena's artesunate as the standard of care for severe malaria; European regulators approved Indena's Ginkgo extract as a pharmaceutical in Germany. One Italian family-controlled company with 1921 origins controls critical botanical API supply chains for at least 4 separate therapeutic categories on the WHO Essential Medicines List.
Indena S.p.A. ↗Did you know2024
Indena's botanical extraction platform simultaneously serves pharmaceutical drug manufacturing (regulated APIs for oncology, anti-infectives), nutraceutical dietary supplements (standardized plant extracts for brain health, liver health — ginkgo biloba, silymarin), and cosmetic actives (plant compounds for skincare, anti-aging formulations). The same Italian extraction facilities, scientific expertise, and plant sourcing networks serve three entirely separate regulatory categories (pharmaceutical API, dietary supplement ingredient, cosmetic active) from the same botanical raw materials. When a plant source faces a harvest shortage (Chinese yew trees for paclitaxel, specific Mediterranean plant species for other AIs), all three markets — drug manufacturing, supplement manufacturing, cosmetics — compete for the same dwindling plant extract.
Indena S.p.A. ↗Origin2023
Indena S.p.A. was founded in 1921 in Milan as the industrial botanical extraction subsidiary of Recordati (one of Italy's oldest pharmaceutical companies, founded 1926 but with earlier origins). Italy's long tradition of herbal medicine and botanical pharmacy was the cultural context for Indena's founding — the Po Valley region had established botanical processing infrastructure dating to the Renaissance era when Italian apothecaries were Europe's leading pharmacists. Indena grew alongside 20th century pharmaceutical chemistry, developing GMP-certified extraction processes for botanical compounds as plant-derived drugs transitioned from folk medicine to regulated pharmaceutical APIs.
Indena S.p.A. ↗